American College of Chest Physicians

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Retrieved on: 
Thursday, October 12, 2023
Health, Genetics, Clinical Trials, General Health, Cardiology, Biotechnology, Annual general meeting, Diagnosis, UIP, Physician, American College of Chest Physicians, Radiology, American College, ILD, Connective tissue, Idiopathic pulmonary fibrosis, HRCT, UCLA Health, CT, Vicki Belo, Interstitial lung disease, Scar, Disorder, Fibrosis, Patient, Medical imaging, Medical device, Pulmonology

(Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).

Key Points: 
  • (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).
  • The studies also underscore the challenge of identifying usual interstitial pneumonia (UIP) in patients being evaluated for ILD.
  • The studies presented at the CHEST Annual Meeting show that adding the Envisia Genomic Classifier to the diagnostic process can improve the ability to detect UIP.
  • For patients with indeterminate HRCT results, adding the Envisia Genomic Classifier more than doubled the UIP diagnostic yield to 49%.

Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Medical Devices, Hospitals, Health, Oncology, Annual general meeting, Lung cancer, Neoplasm, Biomarker, American College of Chest Physicians, NSCLC, American College, PCR, NGS, DNA, AUC, MPH, Disease, Lung, Patient, Sightline (architecture), National Lung Screening Trial, Cleveland, Liquid biopsy, Cleveland Clinic, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.
  • Additionally, the company strengthened its leadership team with the appointment of Mathias Ehrich, M.D., as its chief scientific officer.
  • Earlier this year, the company announced that the Nucleix EpiCheck® Lung Atlas, which utilizes next-generation sequencing (NGS) and is focused on stage I disease, had identified many promising, novel biomarkers for the early detection of lung cancer.
  • “Over the past few months, we’ve made incredible progress on our lung cancer program, having recently premiered data on the Nucleix EpiCheck Lung Atlas and enrolled more than 4,000 patients in the Sightline study,” said Chris Hibberd, chief executive officer of Nucleix.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Abstract, Cleveland Clinic, Lung transplantation, Liquid biopsy, Lung, Pleural disease, Patient, Annual general meeting, American College of Chest Physicians, Sightline (architecture), Pleural cavity, American College, Medical imaging, Lung cancer

The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.

Key Points: 
  • The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.
  • Lung EpiCheck is being developed using markers discovered in Nucleix’s proprietary EpiCheck® Lung Atlas.
  • The Lung Atlas is an early lung cancer detection discovery platform that was constructed and developed as part of a multi-institutional effort to map epigenetic and genetic changes associated with early-stage lung cancer, focusing on stage I disease.
  • Session Title: Late-Breaking Development in Lung Cancer, Lung Transplantation, and Pleural Disease
    The CHEST 2023 abstracts will be available on the journal CHEST website at: https://journal.chestnet.org/meetings .

CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance

Retrieved on: 
Monday, October 2, 2023
Probability, HT, Principal investigator, Moses H. Cone Memorial Hospital, Sepsis, Poster, Patient, American College of Chest Physicians, Diagnosis, Emergency department, Hospital, American College, Medical device

SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation demonstrating the usefulness of SeptiCyte® RAPID in conjunction with clinical assessment of sepsis for informing on antibiotic administration and bundle compliance at the annual meeting of the American College of Chest Physicians (CHEST 2023). The poster, entitled "Potential Impact of a Host Response Gene Expression Sepsis Assay (SeptiCyte® RAPID) in a Tertiary Emergency Department Setting," is designated as Poster #4104 and will be presented on October 10, 2023, from 12 – 12:45 p.m. HT, in Honolulu, Hawaii.

Key Points: 
  • SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ -- Immunexpress , Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation demonstrating the usefulness of SeptiCyte® RAPID in conjunction with clinical assessment of sepsis for informing on antibiotic administration and bundle compliance at the annual meeting of the American College of Chest Physicians (CHEST 2023).
  • The poster, entitled "Potential Impact of a Host Response Gene Expression Sepsis Assay (SeptiCyte® RAPID) in a Tertiary Emergency Department Setting," is designated as Poster #4104 and will be presented on October 10, 2023, from 12 – 12:45 p.m. HT, in Honolulu, Hawaii.
  • "SeptiCyte RAPID in the emergency setting correlated well with high and low probability sepsis assignments, and may facilitate discrimination of intermediate probability sepsis patients," stated Dr. Rakesh Alva, M.D., of Moses Cone Hospital, the Principal Investigator.
  • "These results indicate that SeptiCyte ® RAPID may contribute to actionable guidance for the use of antibiotics and may assist in improving compliance with the Surviving Sepsis Guidelines."

Pulmonary Fibrosis Foundation Names Dr. Franck Rahaghi New President, CEO and Chief Medical Officer

Retrieved on: 
Tuesday, September 5, 2023
San Francisco, Pulmonary fibrosis, Abstract, American College of Chest Physicians, Critical care, Cleveland Clinic, Health policy, University, Education, Internal medicine, Cystic Fibrosis Foundation, ILD, Alternative medicine degrees, Research, Weill Cornell Medical Center, American Thoracic Society, Biomedical engineering, Consultant, Clinical professor, Government, Pulmonology, San Diego, Pulmonary hypertension, MHS, Publication, Biomedicine, MD, Pulmonary Hypertension Association, Berkeley, University of Illinois Urbana-Champaign, FCCP, Rockcastle Regional Hospital and Respiratory Care Center, Nursing care plan, PFF, Health, CCN, Pharmaceutical industry, Nursing, Medicine

CHICAGO , Sept. 5, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced Franck Rahaghi, MD, MHS, FCCP, as its incoming President, Chief Executive Officer and Chief Medical Officer, effective September 15. Following an extensive search, Dr. Rahaghi was selected based on his long-time commitment to care, research, and education in interstitial lung disease (ILD) and pulmonary fibrosis (PF). He will serve in an expanded role as President, CEO and Chief Medical Officer for the PFF.

Key Points: 
  • CHICAGO , Sept. 5, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced Franck Rahaghi, MD, MHS, FCCP, as its incoming President, Chief Executive Officer and Chief Medical Officer, effective September 15.
  • He will serve in an expanded role as President, CEO and Chief Medical Officer for the PFF.
  • In 2003, he joined the medical center as Staff Attending in Pulmonary Critical Care and Director of the Pulmonary Hypertension Clinic.
  • Dr. Rahaghi succeeds Bill Schmidt, former President and CEO of the PFF, and Dr. Joseph Lasky, the Foundation's former Chief Medical Officer.

Noah Medical Unveils Preliminary First In-Human Trial Results to Standing-Room-Only Audience at AABIP 2023

Retrieved on: 
Wednesday, August 30, 2023
CT, Intervention, Workflow, Navigation, Macquarie University Hospital, GameChanger, Cancer, Pulmonology, Doctor of Philosophy, American College of Chest Physicians, Patient, Physician, Risk, SAN, Diagnosis, American College, FDA, Safety, Biopsy, Pharmaceutical industry, Nursing, Medical imaging, Galaxy

The data was presented at the American Association of Bronchology and Interventional Pulmonology’s annual conference ( AABIP 2023 ) in Chicago.

Key Points: 
  • The data was presented at the American Association of Bronchology and Interventional Pulmonology’s annual conference ( AABIP 2023 ) in Chicago.
  • “Noah Medical was founded with a patient and physician focus to solve the most complex and challenging gaps in early diagnosis and treatment.
  • Noah Medical received FDA clearance for the Galaxy System in March 2023.
  • To learn more about Noah Medical and the Galaxy System, please visit noahmed.com .

Sleep Medicine Expert Dr. Marc Benton Joins BetterNight as Staff Doctor to Expand Footprint in New Jersey

Retrieved on: 
Tuesday, August 8, 2023
Madison, Physician, Summit Health, American Academy, American Thoracic Society, Mount Sinai School District, American Academy of Sleep Medicine, Patient, SAN, Sleep medicine, American College of Chest Physicians, American College, Sleep, Clinical, Castle Connolly Medical, Nursing

Dr. Marc Benton is an esteemed medical professional recognized as a Top Doctor by New Jersey Magazine and Castle-Connolly every year since 2001.

Key Points: 
  • Dr. Marc Benton is an esteemed medical professional recognized as a Top Doctor by New Jersey Magazine and Castle-Connolly every year since 2001.
  • Dr. Benton is also a fellow of the American Academy of Sleep Medicine and a member of the American Thoracic Society.
  • As a Staff Doctor with BetterNight, Dr. Benton will play a key role in expanding BetterNight's footprint in New Jersey, "I am excited to join BetterNight and help them make a positive impact on the sleep health of New Jersey residents," said Dr. Benton.
  • "We are thrilled to have Dr. Benton join our team as a Staff Doctor," said David French, CEO of BetterNight.

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Retrieved on: 
Monday, August 7, 2023
Lazarus, Bachelor of Science in Human Biology, University of California, San Diego Performance-Based Skills Assessment, Gilead Sciences, Bronchiolitis, Drug development, University, Therapy, Biochemistry, Internal medicine, PAH, Physician, Pulmonary fibrosis, Boehringer Ingelheim, Health, Patient, Annals of the American Thoracic Society, Associate, American College of Chest Physicians, McGill University, FCCP, Nursing care plan, American College, Orthostatic hypertension, IPF, Boston Medical Center, Pharmaceutical industry, Science

Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.

Key Points: 
  • Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.
  • "Howard’s appointment comes at a critical time in our clinical development," explained Lyn Baranowski , Avalyn’s CEO.
  • In that role, he diagnosed and treated patients with complex pulmonary vascular and interstitial diseases such as IPF and PAH.
  • I’m looking forward to working with the team to advance these product candidates into additional clinical trials and along their path towards approval by the regulatory agencies.”

West Meade Place Rehabilitation and Healthcare Center Becomes First Enhanced Respiratory Care Accredited Facility

Retrieved on: 
Wednesday, July 26, 2023
Enhanced, Executive director, Accreditation, Friends, AARC, Marketing, RRT, Health, American Association for Respiratory Care, Community, Former, Rehabilitation, Patient, Patient safety, American College of Chest Physicians, Frontier Nursing Service, American College, ACCS, Hospital, Nursing, JD, Nashville metropolitan area

NASHVILLE, Tenn., July 26, 2023 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that West Meade Place Rehabilitation and Healthcare Center in Nashville, Tennessee, has met or exceeded the Enhanced Respiratory Care Standards of Care.

Key Points: 
  • West Meade Place Rehabilitation and Healthcare Center in Nashville, Tennessee, has received the Enhanced Respiratory Care Accreditation.
  • West Meade Place is the first healthcare facility in the United States and in the World to receive Enhanced Respiratory Care Accreditation.
  • NASHVILLE, Tenn., July 26, 2023 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that West Meade Place Rehabilitation and Healthcare Center in Nashville, Tennessee, has met or exceeded the Enhanced Respiratory Care Standards of Care.
  • The Enhanced Respiratory Care Standards of Care are supported and endorsed by the American Association for Respiratory Care.

The Inner Circle Acknowledges, Kenneth Bescak, MD, F.A.C.C., as a Distinguished Top Pinnacle Professional for his contributions to the Medical Field

Retrieved on: 
Friday, May 19, 2023
Verde Valley, Ohio State University, Heart failure, Internal medicine, American Heart Association, Cardiac rehabilitation, American College of Cardiology, American Board of Internal Medicine, Cardiovascular disease, National Lipid Association, Multimedia, Private practice, Inner circle, Heart Failure Society of America, American College of Physicians, American Board of Commissioners for Foreign Missions, Patient, Cardiology, American College of Chest Physicians, American College, Medical specialty, Raffles Medical Group, Medical device, Physician, MD, Cottonwood

COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.

Key Points: 
  • COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.
  • Dr. Bescak began his medical educational journey from Ohio State University, Columbus where he received his medical degree.
  • An exemplary diagnostic cardiologist, Dr. Bescak is one of only 500 board-certified lipidologists in the U.S. and one of only seven in Arizona.
  • He was also honored as a distinguished Fellow of the American College of Cardiology and the American College of Chest Physicians.